Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway

Lyle J. Burdine1*, Marie Schluterman Burdine2*, Linley Moreland2, Brad Fogel3, Lisa M. Orr2, Jennifer James3, Richard H. Turnage1, Alan J. Tackett2

1 Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States of America, 2 Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States of America, 3 Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States of America

* These authors contributed equally to this work.
* LJBurdine@UAMS.edu

Abstract

Constitutive activation of the Rearranged during Transfection (RET) proto-oncogene leads to the development of MEN2A medullary thyroid cancer (MTC). The relatively clear genotype/phenotype relationship seen with RET mutations and the development of MEN2A is unusual in the fact that a single gene activity can drive the progression towards metastatic disease. Despite knowing the oncogene responsible for MEN2A, MTC, like most tumors of neural crest origin, remains largely resistant to chemotherapy. Constitutive activation of RET in a SK-N-MC cell line model reduces cell sensitivity to chemotherapy. In an attempt to identify components of the machinery responsible for the observed RET induced chemoresistance, we performed a proteomic screen of histones and associated proteins in cells with a constitutively active RET signaling pathway. The proteomic approach identified DNA-PKcs, a DNA damage response protein, as a target of the RET signaling pathway. Active DNA-PKcs, which is phosphorylated at site serine 2056 and localized to chromatin, was elevated within our model. Treatment with the RET inhibitor RPI-1 significantly reduced s2056 phosphorylation in RET cells as well as in a human medullary thyroid cancer cell line. Additionally, inhibition of DNA-PKcs activity diminished the chemoresistance observed in both cell lines. Importantly, we show that activated DNA-PKcs is elevated in medullary thyroid tumor samples and that expression correlates with expression of RET in thyroid tumors. These results highlight one mechanism by which RET signaling likely primes cells for rapid response to DNA damage and suggests DNA-PKcs as an additional target in MTC.

Introduction

Medullary thyroid carcinoma (MTC) arises from neural crest-derived parafollicular C-cells located in the basal layer of thyroid follicles and accounts for 5–10% of thyroid cancers. 20–30%
of MTC are a hereditary form known as multiple endocrine neoplasia type 2A or B (MEN2A, 2B) and familial medullary carcinoma (FMTC) [1, 2]. Total thyroidectomy and lymph node dissection is the curative treatment for MTC. However, advanced metastatic MTC is inoperable with a 5-yr. survival rate less than 28% (American Cancer Society, 2010). Additional investigation into the cellular mechanisms driving MTC chemoresistance is warranted.

98% of MEN2A cases are caused by germline mutations in the RET (REarranged during Transfection) proto-oncogene that encodes for a receptor tyrosine kinase, which exists in one of two alternatively spliced variants, RET 9 or RET 51 [2,3]. Although the two variants differ by the addition of either 9 or 51 residues at the C-terminal, they display similar downstream signaling effects. Upon dimerization with its ligand, glial cell line–derived neurotrophic factor (GDNF) family ligand (GFL), RET is activated through autophosphorylation of intracellular tyrosine residues. Activation results in stimulation of signaling pathways involved in cell motility, proliferation, differentiation and survival via the mitogen activated protein kinase (RAS/MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways [4]. RET mutations found in MEN2A are dominant gain of function mutations that allow for RET to self-dimerize and be constitutively active [2]. Activation leads to tumorigenesis by upregulating cell division and proliferative processes. The RET signaling program has been studied extensively and multiple clinical trials have been carried out using receptor tyrosine kinase inhibitors or RET small molecule inhibitors to treat MEN2A. Although there is a clear genotype/phenotype relationship seen with RET mutations and the development of MEN2A, these drugs only resulted in marginal response and advanced metastatic MEN2A remained largely resistant [5, 6]. We are interested in investigating the mechanism by which those cells executing a RET oncogenic program increase their capacitance to absorb genotoxic stress.

Evidence suggests that changes to chromatin structure are the earliest events to occur in the transformation of a normal cell [7]. We hypothesized that the constitutive activation of RET drives the formation of MEN2A by altering chromatin machinery (e.g., DNA damage repair) to favor the generation of a highly drug resistant cell population. This work set out to elucidate responsible mechanisms.

Materials and Methods

Cell culture

SK-N-MC cells stably expressing either a RET expression construct containing the extracellular and transmembrane domains of the EGF receptor linked to either the RET9 isoform, RET51 isoform intracellular domains or an empty vector were kindly provided by Dr. Michael Skinner (UT Southwestern Medical Center, Dallas, TX). Unmodified SK-N-MC cells are an established cell line obtainable from ATCC (Manassas, VA). Cells were maintained at 95% air and 5% CO2 at 37°C and grown in MEMS medium (Life Technologies, Grand Island, NY) supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA), pen/strep, and 400 μg of G418 (Hyclone, Logan, UT) for continued selection. Cells were routinely checked for RET expression by western blot analysis. TT cells (CLR-1803) were obtained from ATCC and maintained in F-12K medium with 10% FBS and pen/strep.

Nuclei isolation

TT cells were grown in 6-well plates for nuclei isolation. Cells were washed twice with ice cold PBS, scraped and centrifuged at 3000 rpm for ten minutes. PBS was removed and pellets were resuspended in hypotonic lysis buffer (10 mM Tris-HCL pH 7.9, 1.5 mM MgCl2, 5 mM KCl, protease inhibitors and phosphatase inhibitors (Roche, Indianapolis, IN)) and incubated on ice for ten minutes. Lysates were centrifuged for five minutes at 6000 rpm at 4°C. Supernatant
containing the cytoplasmic fraction was removed and the pellets were resuspended in nuclear
extraction buffer (50 mM Tris-HCl pH 7.9, 0.5 M NaCl, 2mM EDTA, 10% sucrose, 10% glucose, protease inhibitors and phosphatase inhibitors) and incubated on ice for 30 minutes with vortexing every ten minutes. Lysates were centrifuged for 30 minutes at 14,000 rpm and the supernatant containing nuclei were stored at -20°C until they were used for western blot.

Western blot
Cells were plated in 6-well culture dishes (6X10^5 cells/well) and allowed to adhere overnight. Protein lysates were obtained by rinsing cells once with PBS and lysing cells with a Triton X-100 lysis buffer (40 mM Tris pH 7.4, 120 mM NaCl, 0.5% Triton X-100, 0.3% SDS, protease inhibitors and phosphatase inhibitors (Roche, Indianapolis, IN). Lysates were resuspended in 2x BME sample buffer and boiled for five minutes prior to being separated on SDS-PAGE Tris-glycine 4–20% gradient gels (Bio–Rad, Hercules, CA). For analysis of DNA-PKcs, nuclear lysates were separated on NuPage 3–8% Tris-Acetate gels (Bio-Rad). Gels were transferred onto nitrocellulose membranes for 3 hours at 30 V (Tris-Acetate gels were transferred overnight in the cold room at 15 V). Immunoblotting was performed using the following antibodies: RET 9, RET (C-19) sc-167 (Santa Cruz, Dallas, TX), RET 51, RET (C-10) sc-1290 (Santa Cruz), p-RET (Tyr 1062) R sc-20252-R (Santa Cruz), Akt1 (C73H10) #2938 (Cell Signaling, Danvers, MA), p-Akt (ser473) (193H12) #4058 (Cell Signaling), GAPDH (14C10) #2118S (Cell Signaling), DNA-PKcs ab53701 (Abcam, Cambridge, MA), p-DNA-PKcs (p-S2056) ab18192 (Abcam), Lamin B1 ab16048 (Abcam) and pERK 4370S (Cell Signaling). All HRP-conjugated secondary antibodies were from Jackson Immuno Laboratories and used at 1:25000. For treatment with the RET inhibitor, RPI-1 (R8907, Sigma-Aldrich) at 50 μM (RET cells) and 5 μM (TT cells) was supplemented in the media for 24 hours prior to harvesting cells for western blot analysis.

Cell Viability Assay
To monitor the sensitivity of RET cells or TT cells to chemotherapy cell viability assays were performed. Empty vector (EV, control) cells along with cells containing RET 9 and RET 51 isoforms were plated in 96-well plates (10K/well) and allowed to adhere overnight. Medium was replaced with medium containing doxorubicin (DOX) (D1515, Sigma Aldrich, St. Louis, MO) at 0 nM, 100 nm, 250 nM and 500nM. TT cells were also plated in 96-well plates (10K/well) and allowed to adhere overnight before DOX was added to fresh medium at 100nM. In assays looking at the effect of DNAPKcs inhibition, cells were treated with NU7441 inhibitor (KU-57788, Selleckchem, Houston, TX) with or without DOX at 1.0 and 2.0 μM (1 μM for TT cells). After 24 hours, plates with RET cells were removed from the incubator and measured for cell viability using the CellTiter-Glo Luminescent Cell Viability Assay kit (# G7572 Promega, Madison, WI) according to the manufacturer’s protocol. Due to the slow growth rate of TT cells, the assays were performed 4 days after drug was applied. Luminescence was measured on a Perkin Elmer Victor 3V 1420 Multilabel plate reader. The assay was performed in triplicate and statistical analysis performed by standard t tests.

Histone extraction from isolated nuclei
Histones and chromatin binding proteins were isolated from EV, RET 9 and RET 51 cells by H2SO4 extraction. Nuclei were isolated from 1X10^7 cells of each cell line and washed in 1X PBS then centrifuged for five minutes at 2000 rpm. Cells were resuspended in 1 ml of hypotonic lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 0.4 mM PMSF, protease and phosphatase inhibitors). Cell lysis mix was rotated for 30 minutes at 4°C. Following lysis, samples were centrifuged for ten minutes at 10,000 rpm and the nuclei were
resuspended in 200 μl of 0.4N H2SO4. Samples were allowed to mix overnight at 4°C. The next day, samples were centrifuged for ten minutes at 13,000 rpm at 4°C and extracted histone pellets were resuspended in 66 ul of 100% TCA and incubated on ice for 30 minutes. Histones were centrifuged for ten minutes at 13,000 rpm and washed twice in ice cold 100% acetone. Pellets were allowed to completely air dry before being resuspended in H2O. Extraction was performed in biological triplicate for mass spectrometry analysis.

**Mass Spectrometry**

Preparation of protein samples and analysis of data was performed as previously reported by our laboratory and detailed in [8–10]. In short, ten μg of histones were separated on a 4–12% Bis-Tris gradient gel (Life Technologies) and stained with Coomassie Blue (manufacturer’s protocol, Bio-Rad) to visualize proteins. Bands were cut out of the gel and gel pieces containing histones and nuclear associated proteins were diced into smaller pieces for in-gel trypsin digest. Gel pieces were destained in 50% methanol, 100 mM ammonium bicarbonate, followed by reduction in 10 mM Tris[2-carboxyethyl] phosphine and alkylation in 50 mM iodoacetamide. Gel slices were then dehydrated in acetonitrile, followed by addition of 100 ng porcine trypsin (Promega) in 100 mM ammonium bicarbonate and incubation at 37°C for ~14 hours. Peptide products were then acidified in 0.1% formic acid. Tryptic peptides were analyzed by nanoflow LC-MS/MS with a Thermo Orbitrap Velos mass spectrometer equipped with a Waters nanoACQUITY LC system. A total of 486 proteins were identified by a Mascot human database search. Mascot results were uploaded into Scaffold 4 (version 4.00.01) for viewing the proteins and peptide information. A false discovery rate of 1% was used as the cut off value. In order to identify proteins significantly altered between our control lines and those overexpressing RET 9 and 51, we used spectral counting normalized by the Normalized Spectral Abundance Factor (NSAF) method described previously by Byrum S. et al. [8]. Following log transformation of NSAF values, standard Ttests were performed to identify significant proteins. A p-value of < 0.05 was the cutoff for significance.

**Immunocytochemistry**

EV, RET 9 and RET 51 cells were plated in 8-well chamber slides (Fisher Sci., Pittsburgh, PA) at 5 X 10⁴ and allowed to adhere overnight. The following day medium was removed and cells washed once in PBS. Cells were fixed in acetone for twenty minutes at -20°C. Cells were washed once in PBS and blocked in 5% FBS/PBS for one hour at room temperature. Following blocking, primary antibody was added to cells (p-DNA-PKcs (p-S2056) ab18192 (Abcam)) at 1:50 dilution and incubated overnight at 4°C. Primary antibody was removed and cells were washed gently with PBS 3 X 5 minutes at room temperature. Secondary antibody (Cy3-AffiniPure donkey anti-rabbit antibody, Jackson ImmunoResearch, 711-165-152) at a 1:1000 dilution was applied for one hour at room temperature. Cells were washed 3 X 5 minutes in PBS and counterstained with DAPI (Prolong Gold antifade, P36931, Life Technologies) then coverslipped. Images were taken with a Zeiss AxiosImager Z1 microscope and an attached Zeiss AxioCam MRc5 camera fitted with a Cy3 filter. Ten 20X images were taken of each condition. A blind observer recorded the total number of nuclei along with the number of positive nuclei. Data is displayed as % positive nuclei. Standard Ttests were performed for statistical analysis.

**Immunohistochemistry**

Parafin-embedded formalin-fixed human thyroid tissue microarrays were purchased from US BioMax Inc. (Rockville, MD). Staining was performed by the UAMS Pathology Core following standard staining methods. Antibodies used were p-DNA-PKcs (p-S2056) ab18192 (Abcam),
p-RET (Tyr 1062)-R sc-20252-R (Santa Cruz), pERK 1/2 (Thr 202/Tyr 204) sc-16982 (Santa Cruz), pAKT (phospho S473) ab66138 (Abcam). Images were taken using a Zeiss AxioImager Z1 microscope and an attached Zeiss AxioCam MRc5 camera. The level of staining was graded by a blinded pathologist and scaled from 0–3 (0—no staining, 1—light, 2—moderate, 3—high). Chi tests were performed to determine the significance of our findings. p values of ≤ 0.05 were considered significant.

Results

The RET signaling pathway has previously been analyzed in a modified SK-N-MC cell line that does not naturally express the RET receptor but does contain most of the known components of the RET signaling pathway [11–14]. This cell line was made to stably express a chimeric vector containing the EGF extracellular binding domain linked to the RET 9 isoform intracellular signaling domain or the RET 51 intracellular signaling domain. Published data show that when the RET signaling pathway is activated in these cells by binding of EGF present in the media, they become resistant to doxorubicin therapy [15]. Although a chimeric and artificial signaling molecule, this cell line, provided us with a cost effective option for identifying components of the RET pathway that are involved in chemoresistance. GDNF, the natural RET ligand, is not easily used in recombinant form nor is it easily added to the media in the quantities required for a proteomic screen. In Fig 1A it is apparent that in our standard growth conditions the cytoplasmic domain of both isoforms of RET are phosphorylated indicating activation of the pathway. In Fig 1B, all three cell lines were exposed to increasing concentrations of doxorubicin, a common chemotherapeutic agent utilized clinically and known to cause double stranded DNA breaks (DSB). Consistent with previous results [15], the presence of activated RET signaling reduces cell death despite identical cell growth and survival rates under non-genotoxic conditions (Fig 1B). These results suggest that RET signaling confers an increased capacitance to withstand DNA damage. We next sought to investigate differences in chromatin and associated proteins upon activation of RET signaling.

![Fig 1. Increased expression of RET isoforms increases resistance to chemotherapy. A) Western blot analysis of RET lines show expression and phosphorylation of either RET 9 or RET 51 isoforms only in overexpressing lines and not in the control EV cells. B) RET expression causes cells to be resistant to doxorubicin treatment (DOX). *p< 0.01, error bars = s.d.](https://doi.org/10.1371/journal.pone.0127943.g001)
As an initial approach to investigate alterations in chromatin-templated activities in RET stimulated cells, we performed a proteomic screen on acid extractable proteins from nuclei isolated from both our control and RET activated cell lines. A simple protein extraction from cells using 0.4M sulfuric acid provides for extraction of histones as well as other basic nuclear associated proteins, e.g. HMG proteins, nucleosome binding proteins [16]. Proteins isolated from our nuclear preps were resolved by SDS-PAGE, visualized by Coomassie-staining, and subjected to in-gel trypsin digestion as previously reported in our laboratory [16–18]. Tryptic peptides were analyzed with high resolution tandem mass spectrometry (Thermo Velos Orbitrap mass spectrometer coupled to a Waters nanoACQUITY LC system) and identified with Mascot software as previously reported [8–10]. Since we were interested in chromatin-templated activities, we first looked for differences in levels of histone posttranslational modifications (PTMs) including acetylation and methylation. A quantitative analysis of histone PTMs in the three cell lines did not uncover bulk changes in PTM levels (data not shown). Of note, we were unable to identify phosphorylation sites by this method. We next analyzed the proteomic data for proteins, other than histones, that change nuclear levels in response to RET signaling. Using a quantitative analysis of the proteomic data [8–10], we identified a series of chromatin-associated proteins (486 proteins in total) with altered expression (108 of 486 showing altered expression) in RET stimulated cells—one of which was DNA-PKcs. The amount of DNA-PKcs isolated from nuclear associated protein preps was increased by ~24-fold in RET 9 and ~14-fold in RET 51 lines. Table 1 highlights proteins identified with a significant change in expression in both RET 9 and RET 51. A complete list is provided in S1 Table. Given the ability of RET signaling to promote chemoresistance, we were particularly interested in immediately investigating the effect DNA-PKcs was having in our model system of genotoxic stress.

The catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is a 460 kDa polypeptide member of the PI3k family that was initially discovered to be a key component in the double stranded DNA break repair pathway, non-homologous end-joining (NHEJ). The protein is ubiquitously expressed in cells and localizes to sites of DSB with the Ku70/80 heterodimer [17]. Upon recruitment to chromatin, DNA-PKcs becomes activated via autophosphorylation at

Table 1. List of proteins found to be significantly altered in RET 9 and RET 51 lines compared to control lines.

| Protein Name | RET 9 | RET 51 | Fold Change 9–51 | Expression | Known Fxn |
|--------------|-------|--------|-----------------|-----------|-----------|
| Nucleosome-binding protein | 9.95E-05 | 3.35E-06 | 13.07–16.29 | Increased | Modifies chromatin structure for regulation of transcription and histone compaction |
| Isoform 1 of DNA-dependent protein kinase catalytic subunit | 2.396E-05 | 0.006 | 24.14–14.04 | Increased | Binds chromatin and is required for NHEJ pathway of DNA damage |
| Core histone macro-H2A2 | 0.007 | 0.006 | 6.63–6.71 | Increased | Histone variant of H2A, represses transcription |
| Zinc finger protein 22 | 0.11 | 0.0003 | 6.4–5.22 | Increased | Binds DNA to regulate transcription |
| U4/U6. U5 tri-snRNP-associated protein 1 | 0.02 | 0.02 | 8.24–6.58 | Increased | Binds DNA and regulates RNA splicing |
| High mobility group protein | 0.01 | 0.05 | 0.07–0.17 | Decreased | Transcriptional regulator, chromatin condensation |
| Isoform 1 of Methyl-CpG-binding protein 3 | 0.001 | 0.001 | 0.18–0.18 | Decreased | Recruits histone deacetylases and DNA methyltransferases |
| Isoform 2 of sister chromatid cohesion PDS5 | 0.001 | 0.001 | 0.23–0.23 | Decreased | Involved in chromosome cohesion and DNA replication |
| Eukaryotic translation initiation factor 4E-binding protein 1 | 0.004 | 0.009 | 0.38–0.38 | Decreased | Represses protein translation, involved in response to UV/IR |
| Isoform 1 of Nucleophosmin | 0.0008 | 0.0006 | 0.49–0.53 | Decreased | Histone assembly, cell proliferation |

Fold change ≤1.5 is considered increased expression and between 0.2 and 0.6 is decreased expression.

doi:10.1371/journal.pone.0127943.t001
Phosphorylation of DNA-PKcs at s2056 is elevated in RET expressing cells and can be reduced by RET inhibition

To investigate this hypothesis we analyzed the level of total DNA-PKcs and s2056 phosphorylated DNA-PKcs in our three cells lines (EV, RET9, RET51) grown under normal growth conditions. As expected, there was no significant difference in the total levels of DNA-PKcs in whole cell lysate preps. Given that DNA-PKcs is a ubiquitously expressed protein we did not anticipate detecting changes in total levels, however upon probing for the activated form of DNA-PKcs phosphorylated at s2056 which is highly localized to the nucleus, we discovered that the levels were indeed increased in our RET expressing cell lines there-bye further confirming what we observed by mass spectrometry analysis (Fig 2A). Immunocytochemistry of this phosphorylated form of DNA-PKcs demonstrated that it was indeed present at increased levels in the nuclei of cells with activated RET signaling (Fig 2B and 2C).

After validating our mass spectrometric data we next questioned whether chemical inhibition of RET signaling would reduce phosphorylation of DNA-PKcs. Cells were grown in the

Fig 2. Phosphorylation of DNA-PKcs at s2056 is elevated in RET 9 and RET 51 cells. A) Western blot analysis shows phospho-s2056 (ps2056) (460 Kda) to be elevated in RET9 and RET 51 cell lysates. Total DNA-PKcs was used as loading control. B) Immunocytochemistry of cells plated in chamber slides and stained for ps2056 (red) and Dapi as counterstain (blue). C) ICC revealed a significant increase in ps2056 located in the nuclei of RET 9 and RET 51 cells compared to EV. * p ≤ 0.05, error bars = s.d.

doi:10.1371/journal.pone.0127943.g002
presence or absence of RPI-1, a specific RET inhibitor [24]. In the absence of the chimeric onco-
gene (EV cells) or via chemical inhibition of RET activity we were able to significantly reduce
phosphorylation of DNA-PKcs at s2056 further validating DNA-PKcs as a target of the RET
signaling pathway (Fig 3).

Inhibition of DNA-PKcs partially restores the chemosensitivity of RET
expressing cells

Nu7441, a specific DNA-PKcs inhibitor developed from the wortmannin lead compound, has
100-fold specificity over other PI3 kinases and is effective in cell culture at low micromolar
concentrations [25]. We hypothesized that treatment of these cells with this inhibitor should
render cells with active RET signaling sensitive to chemotherapy. SK-N-MC cells grown in the
presence of Nu7441 proliferated at similar rates to untreated cells as demonstrated in Fig 4A.
Treatment with Nu7441 restored chemosensitivity to doxorubicin in the RET expressing cells.
As expected due to the fact that this protein is critical for DNA damage response, this compound
increased sensitivity of our control EV cell line to doxorubicin.

A primary target of DNA-PKcs enzymatic activity is AKT. Specifically it has been demon-
strated that DNA-PKcs phosphorylates AKT at serine 473 [26]. This phosphorylation event is
well documented as being important to cell survival [26]. Likewise, AKT is well known to be
phosphorylated in response to RET activation at serine 473. Interestingly, inhibition of
DNA-PKcs significantly reduced phosphorylation of AKT in our model system (Fig 4B) con-
firming effective inhibition of DNA-PKcs by Nu7441.

Phosphorylation of DNA-PKcs at s2056 in human medullary thyroid
cancer cells is affected by RET signaling and is important for
chemosensitivity

In order to further confirm that DNA-PKcs is involved in the RET signaling pathway and not a
phenomena unique to our screening system, our next set of experiments were moved into a
more physiologically relevant system, MTC derived human TT cells. TT cells are ideal for
studying components of the RET pathway because they harbor a MEN2A-like mutation in
RET causing the pathway to be constitutively active [27]. We verify this by showing high levels
of RET and pERK in TT cell lysates by western blot analysis (S1 Fig). Further analysis of nucle-
ar extracts in human TT cells revealed as expected that DNA-PKcs is present, active, and phos-
phorylated at s2056 (Fig 5A). Importantly, the phosphorylation of DNA-PKcs at s2056 is
blocked by inhibiting RET with the RPI-1 inhibitor (Fig 5A). Likewise, inhibition of

Fig 3. RET inhibition reduces phosphorylation of DNA-PKcs. EV, RET 9 and RET 51 cells were treated
with the RET inhibitor RPI-1 for 24 hours before cells were harvested and analyzed by western blot. RPI-1
treatment significantly reduced phosphorylation of DNA-PKcs at site s2056 according to Image J analysis.
GAPDH was used as loading control. **p ≤ 0.005, error bars = s.d.
doi:10.1371/journal.pone.0127943.g003
DNA-PKcs with Nu7441 significantly increased TT cell sensitivity to doxorubicin indicated by a decrease in TT cell viability as compared to doxorubicin alone (Fig 5B). This data indicates that inhibition of DNA-PKcs may serve as an effective option for treatment of MTC and warrants further investigation.

Phosphorylated DNA-PKcs is present in human medullary thyroid cancer

With any potential drug target in the lab it is essential to verify at the outset that the target is present in human tumor samples. In order to validate DNA-PKcs as a potential target we obtained commercially available tissue microarrays of multiple MTC samples with normal thyroid controls. We were blinded to the genotype and patient outcomes of these samples. Of the
MTC samples analyzed, 80% stained positive for phosphorylated RET, indicating activity of the RET signaling pathway (Fig 6). All samples that demonstrated RET activity also stained for phosphorylated DNA-PKcs at s2056. Notably, 0/16 control samples demonstrated expression of the phosphorylated form of DNA-PKcs. Fig 7 demonstrates staining of several components of the RET signaling pathway including phospho-ERK and phospho-AKT. This representative staining reveals a similar staining pattern for all four components including DNA-PKcs in these Stage II MTC tumor sample.

Discussion

Despite a recent emphasis on the development of targeted therapy, the vast majority of cancer seen in the clinic is treated with genotoxic agents. As a result, chemoresistance remains the biggest challenge in cancer therapy. Identifying proteins that promote it is critical and could dramatically improve patient survival. Like most tumors with an activated RET proto-oncogene, medullary thyroid cancer is largely resistant to standard chemotherapy and radiation regimens. One hypothesis is that cells expressing the RET program are better equipped to process genotoxic stress. However, treatment of medullary thyroid cancer with RET inhibitors has shown modest efficacy to date in clinical trials for reasons not well understood [28]. It is believed that one of the main causes is simply that tumors are not homogenous and rely on multiple different proteins for survival. Although RET is a major player in the development of MTC, studies using targeted therapy have shown that it is not the only. This observation is therefore motivation to search for additional drug targets within oncogenic signaling pathways. In this study, we identify an unknown component of the RET signaling pathway which is critically involved in the repair of DNA damage, DNA-PKcs. Although the total amount of DNA-PKcs was not different in whole cell extracts of our control versus the RET expressing cell lines, the phosphorylated form of the protein which is highly associated with chromatin and active was significantly elevated. Activation of RET raised the levels of phosphorylated s2056 DNA-PKcs while inhibition of RET significantly reduced DNA-PKcs phosphorylation. Previous research has demonstrated that other receptor tyrosine kinase pathways are capable of activating DNA-PKcs, therefore; it is perhaps not surprising that our research has demonstrated this
phenomena to occur in the RET signaling pathway in MTC as well [29]. This finding is significant because recent studies have highlighted the involvement of DNA-PKcs in chemoresistance and would therefore provide one mechanism by which RET and drives resistance [20–23]. Most importantly, our data shows that inhibition of DNA-PKcs restores chemosensitivity to our RET expressing cells. In order to demonstrate that activated DNA-PKcs is in fact a legitimate drug target we validated our results in human TT cells and probed tissue microarrays of medullary thyroid cancer for the presence of DNA-PKcs phosphorylated at s2056. We demonstrated the presence of the target in 95% of the tumor samples and 100% of those tumors with an active RET signaling pathway. These results suggest that DNA-PKcs would be an interesting drug target for medullary thyroid cancer and perhaps RET expressing tumors in general [30, 31]. By targeting multiple sites along the RET pathway, we may better be able to treat advanced MTC. Currently in the United States there are three phase I clinical trials testing DNA-PKcs inhibition in the treatment of advance solid tumors. (clinicaltrials.gov, 2014)
Supporting Information

S1 Fig. TT cells contain an active RET signaling pathway. (TIFF)

S1 Table. Full List of proteins identified in screen to be altered in RET expressing cell lines. Fold change ≤1.5 is considered increased expression and between 0.2 and 0.6 is decreased expression. (XLSX)

Acknowledgments

We thank Dr. Michael Skinner (UT Southwestern) for providing us with the SK-N-MC RET cell lines and for helpful discussion. We would also like to thank Dr. Sandeep Burma (UT Southwestern) for his technical advice regarding extraction and staining of DNA-PKcs.
Author Contributions

Conceived and designed the experiments: MSB LB. Performed the experiments: MSB LB LM BF JJ LMO. Analyzed the data: MSB LB BF RT AJT. Contributed reagents/materials/analysis tools: MSB LB BF JJ RT AJT. Wrote the paper: MSB LB. Obtained cell lines for use in experiments: LB.

References

1. Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6): 475–85. doi: 10.1016/j.clon.2010.05.002 PMID: 20627492

2. Phay JE, Shah MH (2010) Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16(24): 6936–41. doi: 10.1158/1078-0432.CCR-09-0786 PMID: 20930041

3. Carter MT, Yorne JL, Marcil MN, Martin CA, Vanhome JB, Mulligan LM (2001) Conservation of RET proto-oncogene splicing variants and implications for RET isoform function. Cytogenet Cell Genet 95 (3–4): 169–76. PMID: 12063410

4. Hansford JR, Mulligan LM (2000) Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37(11): 817–27. PMID: 11073534

5. Mologni L (2011) Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem 18(2): 162–75. PMID: 21110809

6. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, et al. (2011) The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 96(6): E991–5. doi: 10.1210/jc.2010-2381 PMID: 21470995

7. Yamada Y, Watanabe A (2010) Epigenetic codes in stem cells and cancer stem cells. Adv Genet 70: 177–99. doi: 10.1016/B978-0-12-380866-0.60007-1 PMID: 20920749

8. Byrum SD, Raman A, Taverna SD, Tackett AJ (2012) ChAP-MS: a method for identification of proteins and histone posttranslational modifications at a single genomic locus. Cell Rep 2(1): 198–205. doi: 10.1016/j.celrep.2012.06.019 PMID: 22840409

9. Byrum SD, Taverna SD, Tackett AJ (2013) Purification of a specific native genomic locus for proteomic analysis. Nucleic Acids Res 41(20): e195. doi: 10.1093/nar/gkt822 PMID: 24030711

10. Byrum S, Avaritt NL, Mackintosh SG, Munkberg JM, Badgwell BD, Cheung WL, et al. (2011) A quantitative proteomic analysis of FFPE melanoma. J Cutan Pathol 38(11): 933–6. doi: 10.1111/j.1600-0560.2011.01761.x PMID: 21883366

11. Pandit SD, O’Hare T, Donis-Keller H, Pike LJ (1997) Functional characterization of an epidermal growth factor receptor/RET chimera. J Biol Chem 272(4): 2199–206. PMID: 8999923

12. van Weering DH, Mederna JP, van Puijenbroek A, Burgering BM, Baas PD, Bos JL (1995) RET receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 11(11): 2207–14. PMID: 8570170

13. van Weering DH, Bos JL (1997) Glial cell line-derived neurotrophic factor induces RET-mediated lamellipodia formation. J Biol Chem 272(1): 249–54. PMID: 8995255

14. van Puijenbroek AA, van Weering DH, van den Brink CE, Bos JL, van der Saag PT, de Laat SW, et al. (1997) Cell scattering of SK-N-MC neuroepithelioma cells in response to RET and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation. Oncogene 14(10): 1147–57. PMID: 9121763

15. Skinner MA, Lackey KE, Freemeriman AJ (2008) RET activation inhibits doxorubicin-induced apoptosis in SK-N-MC cells. Anticancer Res 28(4B): 2019–25. PMID: 18751369

16. Jufvas A, Strålfors P, Vener AV (2011) Histone variants and their post-translational modifications in primary human fat cells. PLoS One 6(1): e15960. doi: 10.1371/journal.pone.0015960 PMID: 21249133

17. Davis AJ, Chen DJ (2013) DNA double strand break repair via non-homologous end-joining. Transl Cancer Res 2(3): 130–143. PMID: 24000320

18. Chen BP, Chan DW, Kobayashi J, Burm A, Asaithamby A, Morotomi-Yano K, et al. (2005) Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 280(15): 14709–15. PMID: 15677476

19. An J, Huang YC, Xu QZ, Zhou LL, Shang ZF, Huang B, et al. (2010) DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression. BMC Mol Biol 11: 18. doi: 10.1186/1471-2199-11-18 PMID: 20205745
20. Du L, Zhou LJ, Pan XJ, Wang YX, Xu QZ, Yang ZH, et al. (2010) Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat Oncol 5: 70. doi: 10.1186/1748-717X-5-70 PMID: 20704701

21. Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, et al. (2012) Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Mol Cancer Ther 11(8): 1789–98. doi: 10.1158/1535-7163.MCT-11-0535 PMID: 22576130

22. Toulany M, Lee KJ, Fattah KR, Lin YF, Fehrenbacher B, Schaller M, et al. (2012) Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 10(7): 945–57. doi: 10.1158/1541-7786.MCR-11-0592 PMID: 22596249

23. Minjgee M, Toulany M, Kehlbach R, Giehl K, Rodemann HP (2011) K-RAS(V12) induces autocrine production of EGFR ligands and mediates radiosensitivity through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys 81(5): 1506–14. doi: 10.1016/j.ijrobp.2011.05.057 PMID: 21985943

24. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, et al. (2004) Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96(13): 1066–14. PMID: 15240784

25. Zhao Y, Thomas HD, Batey MA, Cowell I, Richardson CJ, Griffin RJ, et al. (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66(10): 5354–62. PMID: 16707462

26. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, et al. (2011) DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13(11): 1069–80. PMID: 22131882

27. Carlomagno F, Salvatore D, Santoro M, de Francisicis V, Quadro L, Panariello L, et al. (1995) Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 207(3): 1022–8. PMID: 7864988

28. Phay JE, Shah MH (2010) Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16(24): 5936–41. doi: 10.1158/1078-0432.CCR-09-0786 PMID: 20930041

29. Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76(2): 157–61. PMID: 16024112

30. Narita N, Tanemura A, Murali R, Scolyer RA, Huang S, Arigami T, et al. (2009) Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 28(34): 3058–68. doi: 10.1038/onc.2009.164 PMID: 19561646

31. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM (2006) Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 22(11): 627–36. PMID: 16979782